menu
    • menu
    [{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo Pharm \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Urology","graph2":"Approved","graph3":"BioSpecifics","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Urology","amount2New":0.54000000000000004,"dosageForm":"Injection","sponsorNew":"BioSpecifics \/ Endo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"BioSpecifics \/ Endo Pharmaceuticals"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Approved","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Endo International \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Collagenase Clostridium Histolyticum

    Menu

    Collagenase Clostridium Histolyticum

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participant...

                            Details : EN3835 (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is being investigated for plantar fibromatosis.

                            Brand Name : EN3835

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 13, 2023

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participant...

                            Details : Phase 2 study participants receiving up to 3 doses of Xiaflex (collagenase clostridium histolyticum) showed improvement in change from baseline ifor affected shoulder at Day 95, compared to those study participants receiving placebo was not significant.

                            Brand Name : Xiaflex

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 01, 2022

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the An...

                            Details : Qwo (collagenase clostridium histolyticum-aaes), is a prescription medicine used to treat moderate to severe cellulite in the buttocks of adult women, may cause serious side effects including allergic.

                            Brand Name : Qwo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 05, 2022

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioSpecifics

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioSpecifics

                            Country arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Urology

                            Study Phase : Approved

                            Sponsor : Endo Pharm

                            Deal Size : $540.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Endo Completes Acquisition of BioSpecifics

                            Details : BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.

                            Brand Name : Xiaflex

                            Molecule Type : Large molecule

                            Upfront Cash : $540.0 million

                            December 02, 2020

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Urology

                            Highest Development Status : Approved

                            Sponsor : Endo Pharm

                            Deal Size : $540.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's A...

                            Details : Endo International will present data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women during the American Society for Dermatologic ...

                            Brand Name : Qwo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 09, 2020

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Endo Pharm

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Endo to Present Qwo™ (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery & Aesthetic ...

                            Details : Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.

                            Brand Name : Qwo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 24, 2020

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth